• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Recent Advances in the Study of 6-Fluoro-1-methylquinazolin-4(1H)-one (CAS: 1379685-42-3)

6-Fluoro-1-methylquinazolin-4(1H)-one (CAS: 1379685-42-3) is a fluorinated quinazolinone derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, synthetic routes, and biological activities.

The compound's unique structure, featuring a fluorine atom at the 6-position and a methyl group at the 1-position of the quinazolinone core, contributes to its enhanced stability and bioavailability. Recent synthetic methodologies have focused on optimizing the yield and purity of 6-Fluoro-1-methylquinazolin-4(1H)-one, with particular emphasis on green chemistry approaches. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported a novel catalytic system that significantly reduces the use of hazardous reagents while maintaining high efficiency.

In terms of biological activity, 6-Fluoro-1-methylquinazolin-4(1H)-one has shown promising results as a scaffold for designing inhibitors targeting EGFR (Epidermal Growth Factor Receptor) and other tyrosine kinases. A recent preclinical study demonstrated that derivatives of this compound exhibit potent anti-proliferative effects against non-small cell lung cancer (NSCLC) cell lines, with IC50 values in the low micromolar range. These findings suggest its potential as a lead compound for anticancer drug development.

Additionally, research has uncovered its antimicrobial properties, particularly against Gram-positive bacteria. A 2022 study in Bioorganic & Medicinal Chemistry Letters highlighted its efficacy in inhibiting bacterial cell wall synthesis, making it a candidate for further exploration in antibiotic resistance research. The compound's mechanism of action appears to involve interference with key enzymatic processes, though further elucidation is required.

Despite these advancements, challenges remain in the clinical translation of 6-Fluoro-1-methylquinazolin-4(1H)-one-based therapeutics. Issues such as metabolic stability, toxicity profiles, and pharmacokinetic properties need to be addressed through rigorous preclinical testing. Recent efforts have focused on structural modifications to improve these parameters, with some derivatives already entering early-stage clinical trials.

In conclusion, 6-Fluoro-1-methylquinazolin-4(1H)-one (CAS: 1379685-42-3) represents a versatile and promising scaffold in medicinal chemistry. Its applications span from oncology to infectious diseases, and ongoing research continues to uncover new therapeutic potentials. Future studies should prioritize the optimization of its pharmacological properties and the exploration of combination therapies to maximize its clinical impact.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)